Pieris Pharmaceuticals (NASDAQ:PIRS)‘s stock had its “buy” rating reissued by investment analysts at William Blair in a note issued to investors on Friday, AnalystRatings.com reports.
The analysts wrote, “Wenzel is considered a global expert in the treatment of asthma and has extensive experience in conducting clinical trials in asthma patients, having been a lead author on the Phase II trials of Dupixent (Wenzel et al., 2016) and a co-author in the Phase III pivotal trial. The call reaffirmed that FeNO is a well-validated clinical marker of biological activity in patients with asthma, and our belief that there is a significant market opportunity for PRS-060, an inhaled Anticalin targeting IL-4Rα.””
Several other research firms have also recently weighed in on PIRS. Robert W. Baird cut shares of Pieris Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price target for the company. in a report on Tuesday, July 30th. Cowen restated a “buy” rating on shares of Pieris Pharmaceuticals in a report on Monday, May 13th. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Pieris Pharmaceuticals in a report on Thursday, August 1st. ValuEngine upgraded shares of Pieris Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. Finally, Zacks Investment Research cut shares of Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 6th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $5.67.
A number of hedge funds and other institutional investors have recently bought and sold shares of PIRS. Dimensional Fund Advisors LP bought a new position in shares of Pieris Pharmaceuticals during the fourth quarter valued at $374,000. Bank of America Corp DE increased its holdings in shares of Pieris Pharmaceuticals by 793.1% during the fourth quarter. Bank of America Corp DE now owns 277,370 shares of the biotechnology company’s stock valued at $739,000 after acquiring an additional 246,312 shares in the last quarter. D. E. Shaw & Co. Inc. increased its holdings in shares of Pieris Pharmaceuticals by 107.0% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 49,904 shares of the biotechnology company’s stock valued at $133,000 after acquiring an additional 25,794 shares in the last quarter. Deutsche Bank AG increased its holdings in shares of Pieris Pharmaceuticals by 41.8% during the fourth quarter. Deutsche Bank AG now owns 190,266 shares of the biotechnology company’s stock valued at $505,000 after acquiring an additional 56,072 shares in the last quarter. Finally, BNP Paribas Arbitrage SA bought a new position in shares of Pieris Pharmaceuticals during the first quarter valued at $36,000. 57.88% of the stock is currently owned by hedge funds and other institutional investors.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Featured Story: What moving averages are used to define a golden cross?
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.